Please provide your email address to receive an email when new articles are posted on . Atezolizumab monotherapy induced objective responses in more than one-third of patients. No treatment-related ...

Alveolar soft part sarcoma (ASPS) remains one of the rare and enigmatic soft tissue malignancies, principally affecting adolescents and young adults. Despite its low incidence, recent research has ...

The death of 19-year-old Alex Duong from alveolar rhabdomyosarcoma has drawn public attention to a rare and aggressive cancer ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic ...

A clinical trial has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S.

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis. This is an ASCO ...

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS) ...

Aug 7, 2022 Aug 7, 2022 Updated Aug 7, 2022 LOUISVILLE, Ky. (WDRB) -- “To always have hope no matter what comes up, you can either choose fear or hope, and I feel like hope is always the best option.” ...

Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a poor prognosis and no established therapy. Recently, encouraging responses to immune checkpoint inhibitors have been reported. We ...

Cancer, the second leading cause of death worldwide, is more likely to respond to effective treatment if identified early before metastasizing, resulting in a greater probability of surviving. Science ...